Real-World Evidence Could Speed Development Of Drugs Offering Incremental Improvements
US FDA Commissioner Gottlieb says common diseases need new treatments and argues streamlining trials may pique industry interest.
You may also be interested in...
US may have substantial drug purchasing muscle, as evident in latest CMS proposal to reform Medicare Part B, but still needs pharma to force prices down.
Under new platform, drugs could soon be approved with accompanying software applications that could monitor adverse events or patient compliance without a separate premarket device review.
New draft guidance says citizen petition abuses will be referred to FTC and publicly called out as attempts to delay ANDA approvals.